kra next
top-lin beat bottom-lin slightli rais guid
report revenu in-lin consensu
adjust ep slightli beat consensu revenu adjust ep
guidanc rais slightli
respect continu share repurchas program buy
back expect repurchas anoth updat
estim epogen aranesp neulasta reiter buy rate strong
fundament underappreci pipelin
enbrel neulasta beat help drive top-line
report enbrel revenu consensu expect
driven segment growth benefit net sell price despit impact
deliv global sale consensu note neulasta
benefit onetim purchas us biomed advanc research
develop author neulasta would miss consensu benefit
exclud still encourag neulasta perform face on-going
biosimilar competit launch us amgn wider usual guidanc rang
driven uncertainti surround potenti addit biosimilar entri amgn
biosimilar portfolio deliv bring consensu
aimovig came expect vs consensu howev includ
signific neg impact inventori destock net price
clinic data next asco
current develop kra cancer mutat target inhibitor
solid tumor lung colon pancreat cancer uniqu
abil target kra elus drug discoveri effort
consid monotherapi combin therapi
includ inhibitor depend tumor type expect present
phase dose escal data american societi clinic oncolog
annual meet may given preval kra mutat
variou cancer see size address market continu
believ amgn pipelin under-appreci
full definit iqmethod sm measur see page
net dbt
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
biopharmaceut compani
develop manufactur market biolog
therapi oncolog inflamm
five key market product among top
sell pharmaceut product world
collect revenu nearli
buy rate base new product launch
anticip biosimilar launch
help drive top-lin growth strong
cash posit also allow addit share
buyback dividend payment transform
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
price object base multipl ep estim
non-gaap ep exclud stock option expens amort intang asset
restructur charg non-cash expens multipl support
strong cash flow gener dividend payout choic multipl
line major pharma peer
downsid risk po greater-than-forecast declin esa neupo
enbrel revenu greater-than-expect price pressur europ potenti drug
price system restructur us failur bring new pipelin product
upsid risk po less-than-forecast declin key product revenu
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
